Literature DB >> 11551376

Use of gene markers to guide antihypertensive therapy.

S T Turner1, G L Schwartz, A B Chapman, E Boerwinkle.   

Abstract

Sequencing of the human genome has elevated the potential for genetic information to aid in the prevention, diagnosis, and treatment of common chronic diseases. One beneficial application of genetic information is the identification of variants that influence response to pharmaceutical agents used to lower blood pressure and prevent target organ complications of hypertension. Knowledge of genetic variants that influence blood pressure response to antihypertensive drugs may allow more individualized tailoring of antihypertensive drug therapy, and provide greater insight into the molecular mechanisms regulating blood pressure levels and causing hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551376     DOI: 10.1007/s11906-001-0059-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  44 in total

1.  Shattuck lecture--medical and societal consequences of the Human Genome Project.

Authors:  F S Collins
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

Review 2.  Molecular mechanisms of human hypertension.

Authors:  R P Lifton; A G Gharavi; D S Geller
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

3.  A pharmacogenetic approach to blood pressure in Lyon hypertensive rats. A chromosome 2 locus influences the response to a calcium antagonist.

Authors:  M Vincent; N J Samani; D Gauguier; J R Thompson; G M Lathrop; J Sassard
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

4.  National Ambulatory Medical Care Survey: 1993 summary.

Authors:  C Nelson; D Woodwell
Journal:  Vital Health Stat 13       Date:  1998-04

5.  The association between salt sensitivity of blood pressure and some polymorphic factors.

Authors:  S Kojima; T Inenaga; H Matsuoka; M Kuramochi; T Omae; Y Nara; Y Yamori
Journal:  J Hypertens       Date:  1994-07       Impact factor: 4.844

6.  Feasibility study of N-of-1 trials with blood pressure self-monitoring in hypertension.

Authors:  G Chatellier; M Day; G Bobrie; J Menard
Journal:  Hypertension       Date:  1995-02       Impact factor: 10.190

Review 7.  Adducin in essential hypertension.

Authors:  P Manunta; C Barlassina; G Bianchi
Journal:  FEBS Lett       Date:  1998-06-23       Impact factor: 4.124

8.  Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension.

Authors:  H Hiraga; T Oshima; M Watanabe; M Ishida; T Ishida; T Shingu; M Kambe; H Matsuura; G Kajiyama
Journal:  Hypertension       Date:  1996-03       Impact factor: 10.190

Review 9.  [Genetic polymorphism of the G-protein beta3 subunit, obesity and essential hypertension].

Authors:  W Siffert; D Rosskopf; R Erbel
Journal:  Herz       Date:  2000-02       Impact factor: 1.740

10.  Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension.

Authors:  D Cusi; C Barlassina; T Azzani; G Casari; L Citterio; M Devoto; N Glorioso; C Lanzani; P Manunta; M Righetti; R Rivera; P Stella; C Troffa; L Zagato; G Bianchi
Journal:  Lancet       Date:  1997-05-10       Impact factor: 79.321

View more
  2 in total

Review 1.  Gene markers and antihypertensive therapy.

Authors:  Stephen T Turner; Gary L Schwartz
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

Review 2.  Remission and regression of diabetic nephropathy.

Authors:  Peter Hovind; Lise Tarnow; Hans-Henrik Parving
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.